



A STUDY OF NON ALCOHOLIC FATTY LIVER DISEASE PATIENTS WITH METABOLIC SYNDROME

**Dr. Bhanu
Prakash. V**

Post Graduate Dept Of General Medicine, viswabharathi Medical College Kurnool

**Dr. S. S. Rama
Kalyana Praveen**

MD General Medicine, assistant Professor, dept of General Medicine, viswabharathi Medical College Kurnool*Corresponding Author

**Dr. Lavanya
Reddy. M***

MD General Medicine, Professor, dept Of General Medicine, Viswabharathi Medical College Kurnool. *Corresponding Author

ABSTRACT **Background:** Non-alcoholic fatty liver disease (NAFLD) has been rising in incidence in the past two decades in developing nations like India as well as in many western nations and is being taking over the position of most common liver disease in the world. **Aims & objectives:** To study ultrasonographically diagnosed NAFLD with various grades and its association with metabolic syndrome and its components. **Material and Methods:** The study was cross sectional descriptive study of patients with NAFLD, attending OPD and in patients of the Department of general Medicine, tertiary care hospital. All patients with as NAFLD were investigated for metabolic syndrome according to the NCEP ATP 3 Criteria and association between NAFLD and metabolic syndrome was studied. **Results:** There was a significance association between fasting blood sugar level and USG grading of NAFLD. Age, HDL, VLDL & SBP were close to the statistical significant level. **Conclusions:** NAFLD found to be in higher degree in all the components of metabolic syndrome. Its early screening will help in modifying the disease course, delaying complications and will also play a major role in preventive complication.

KEYWORDS : Non alcoholic fatty liver disease , Metabolic syndrome, Systolic blood pressure, high density lipoproteins, low density lipoproteins, ultrasonography.

INTRODUCTION

Non Alcoholic Fatty Liver Disease (NAFLD) has been rising in incidence in the past two decades in developing nations like India as well as in many Western nations and is being taking over the position of most common liver disease in the world. The autopsy studies and other non-randomised studies have shown about 21 to 31 % of the individuals in the western nations having NAFLD. Two types of NAFLD have been recognised , namely simple fatty liver and non alcoholic steatohepatitis (NASH).

Simple fatty liver means you have fat in liver , but you may not have any inflammation in your liver or damage to your liver cells .It usually doesn't get worse or cause problems with your liver. most people with NAFLD have simple fatty liver. Non alcoholic steatohepatitis is more serious than simple fatty liver. NASH means you have inflammation in your liver. You may also have damage to liver cells. NASH which may ultimately lead to cirrhosis, hepato cellular carcinoma, cardiovascular disease and death.

Many studies regarding the study of risk factors associated with NAFLD have shown it to be related with increasing age, diabetes mellitus Type 2, obesity and hyperlipidaemia. (1,2) Even visceral obesity and female gender are related with this disease. Further NAFLD patients are at greater risk of severe hepatic disease (non-alcoholic steato hepatitis [NASH]) which may ultimately improve on to cirrhosis, hepato cellular carcinoma, cardiovascular disease and death. (3-5) The Metabolic syndrome(MS) is a combination of risk factors that vastly affects a person's chance for emerging atherosclerotic heart disease (ASCVD), diabetes mellitus type 2 and chronic kidney disease. The common underlying risk factors seems to be obese abdomen, dyslipidaemia, hypertension, abnormal glucose, a pro-thrombotic state, and a pro-inflammatory state.(6,7). The MS is diagnosed by the occurrence of more than three findings: " waist circumference more than 102 cm in Men, more than 88 cm in Women, high Triglycerides (more than 150 mg/dl), Reduced HDL-C level (less than 40 mg/dl in men, less than 50 mg/ dl in women), Increased blood pressure(systolic blood pressure more than 130 mmHg or diastolic blood pressure more than 85 mm Hg) and plasma glucose value 100 - 125 mg/dl or on anti diabetic drug treatment".(9,10)

METHODOLOGY

Study Subjects

Patients with non alcoholic fatty liver both op & ip attending General medicine department

Study Design

This is a cross-sectional descriptive study which was carried out in the medicine department

Ethical Approval

Ethical approval was obtained from Institutional Ethical committee

Inclusion Criteria

- All patients who were diagnosed as fatty liver by abdominal ultrasonography.
- Age more than 18 years
- Patients with metabolic syndrome criteria.

Exclusion Criteria

RESULTS

Fasting blood sugar level and USG grading with p- value of 0.003. Age was close to significance level. VLDL is just insignificant with p value of 0.07. None of the other variables.

Subjects belonged to the age group of 46-60 years. 94(94%) of the study subjects were females. 86(86%) of the study subjects belonged to overweight category. 61(61%) and 29(29%) of subjects belonged to grade II and grade III USG classification. 63(63%) of the study subjects were diagnosed with hypertension. 90(90%) of the study subjects were diagnosed with Diabetes Mellitus. None of the variables were significantly correlated with the USG. However Age, LDL, VLDL and Systolic blood pressure were close to the statistical significant level.

- Subjects < 18 years and who were more than 85 years. In our study, there was a significant association between
- Patients with previous history of harmful alcohol intake.
- Patients with previous jaundice or Hepatitis B positive, HCV positive.
- Patients with previous history of drug use for chronic were significantly correlated with the USG. However Age, ailments - steroids, synthetic oestrogens, heparin, Ca LDL, VLDL and Systolic blood pressure were close to the channel blockers, amiodarone, valproate, antiviral statistical significant level. Majority 59(59%) of the studyagents.

Sample Size

Hundred subjects with NAFLD

Study Duration

18MONTHS (DEC 2020 TO JUNE 2022)

Study Procedure

Subjects were recruited in the study based on the standard American Gastroenterology Association criteria. (8) As per the criteria patients were graded:

Grade 1

- a. Slight diffuse increase in the fine echoes.
- b. Liver appears bright as compare to that of the cortex of the kidney.
- c. Normal visualisation of diaphragm vessel borders.

Grade 2

- a. Moderate diffuse in the fine echoes.
- b. Slightly impaired visualisation of intrahepatic vessels and diaphragm




Figure 1 USG Grading among the study population'

The figure shows that 13 (13%), 61(61%) and 26(26%) of subjects belonged to grade I, grade II and grade III USG classification among the study population.

Grade 3

- a. Marked increase in the fine echoes
- b. Poor or no visualisation of intra hepatic vessels borders, diaphragm and the blood vessels.

In depth history, height, weight examination and medical assessment were carried out only after explaining the procedure and then obtaining informed consent of the patient. All subjects in the study underwent the following investigations:

- i. Complete blood counts,
- ii. Blood sugar,
- iii. Liver function tests,
- iv. HBsAg, anti HCV,
- v. Lipid profile

Statistical Methods

Data was entered using MS-excel data sheet. The Data was analysed using the statistical package for social sciences (SPSS) version 23.0. Descriptive statistics such as frequency and percentage were calculated. Continuous variables were expressed in Mean and Standard Deviation. Association between the groups of USG grades and various study variables predominantly continuous variables will be done by Analysis of Variance test (ANOVA). When the categorical variables were associated with another categorical variable, chi-square test was used. A p-value of 0.05 or less was taken to indicate a statistically significant difference.

Table 1 Association between USG categories and FBS among the study population

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
FBS	I	10	176.50	47.240	128	0.003
	II	61	146.23	20.101	120	
	III	29	158.03	30.293	120	
	Total	100	152.68	28.260	120	

The table shows the association between USG categories and FBS.

Table 2 Association between Age groups and USG categories

	N	Mean	Std. Deviation (SD)	Minimum	Maximum	p-Value (ANOVA test)
AGE	I	10	47.80	10.390	27	0.133
	II	61	48.84	9.529	24	
	III	29	53.14	11.357	33	
	Total	100	49.98	10.161	24	

The table shows the association between USG categories and age groups

Table 3 Association between presence of HTN and USG categories

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
HTN	I	10	144.00	16.303	134	0.945
	II	61	143.41	8.751	130	
	III	29	142.28	27.840	10	
	Total	100	143.14	17.033	10	

The table shows the association between USG categories and SBP.

Table 4 Association between USG categories and VLDL among the study population

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
VLDL	I	10	34.20	8.135	26	0.074
	II	61	30.54	5.784	20	
	III	29	29.24	5.054	22	
	Total	100	30.53	5.947	20	

The table shows the association between USG categories and V LDL.

Table 5 Association between USG categories and LDL among the study population

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
LDL	I	10	105.80	12.200	86	0.297
	II	61	100.75	11.621	82	
	III	29	99.28	10.498	82	
	Total	100	100.83	11.391	82	

The table shows the association between USG categories and LDL.

Table 6 Association between USG categories and WC among the study population

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
WC	I	10	103.00	12.410	85	0.325
	II	61	106.10	10.018	84	
	III	29	103.10	8.139	88	
	Total	100	104.92	9.785	84	

Table 7 Association between USG categories and Triglycerides among the study population

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
TRIGLYC	I	10	184.50	21.792	162	0.333
	II	61	179.20	18.863	109	
	III	29	184.93	15.531	138	
	Total	100	181.37	18.280	109	

The table shows the association between USG categories and Triglyceride.

Table 8 Association between USG categories and HDL among the study population

	N	Mean	Std. Deviation	Minimum	Maximum	p-Value (ANOVA test)
HDL	I	10	36.80	3.425	32	0.455
	II	61	37.36	8.410	26	
	III	29	35.31	5.008	26	
	Total	100	36.71	7.202	26	

The table shows the association between USG categories and HDL

DISCUSSION

The presence of non alcoholic fatty liver disease as a strong predictor for impending metabolic syndrome was proved in our study.

Metabolic Syndrome criteria According to NCEP ATP 3 (10) Out of this, if three factors are found to be contributing to the study subjects it as considered as positive

i. Abdominal obesity indicated by waist circumference measuring more than 102 cm (Men), more than 88cm (women)

ii. Hypertriglyceridaemia: Triglycerides more than or equal to 1.7 mmol/L

- iii. Low HDL cholesterol: Less than 1.0 mmol/L (Men) less than 1.3 mmol/L (women)
- iv. Hypertension: Blood pressure more than or equal to 135/85 mm Hg or on drug
- v. Fasting plasma glucose more than or equal 100mg/dl.

In our study, there was a significant association between Fasting blood sugar level and USG grading with p-value of 0.003. Age was close to significant level. VLDL is just insignificant with p-value of 0.07. None of the other variables were significantly correlated with USG. However age, LDL, VLDL, systolic blood pressure were close to statistical significant level. Majority (59%) of the study subjects belong to the age group of 46-60 years, 94% of the study subjects were females, 86% of the study subject belong to overweight category, 61% and 26% of subjects belong to grade 2 and grade 3 USG. However Age, LDL, VLDL and Systolic blood pressure were close to the statistical significant level. Present statistics on epidemiology, pathophysiology and diagnostic supports the relationship of non-alcoholic fatty liver disease as a likely component in the cluster of metabolic syndrome. Clinical, experimental and epidemiological studies maintain that NAFLD may be the hepatic expression of metabolic syndrome. (11) Because metabolic syndrome can be defined in many different ways, NAFLD might be a more direct predictor of these diseases. (12) Treatment of NAFLD includes weight management, drugs aiming at Insulin resistance and Lipid lowering drugs.

The robust indication provisions lifestyle modifications with weight loss, but there is some proof to support bariatric surgery, medical therapy with insulin-sensitizing agents, and/or pharmacotherapy to encourage weight loss. Cardiovascular disease is the major reason of mortality in patients with NAFLD, so management must include adjustment of cardiovascular risk factors. (13,14)

In a study by Banerjee S et al aimed at studying the association of clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance found that USG detected, defect correlated poorly with HPE. (15)

Bedogni G, et al. conducted a cross-sectional study among 3,345 subjects from Italy. They found that NAFLD was occurring more normal subjects and connected with many findings of the MS. (16)

CONCLUSION

There was a significant association between Fasting blood sugar level and USG grading with p-value of 0.003. Age was close to significance level. VLDL is just insignificant with p value of 0.07. None of the other variables were significantly correlated with the USG. However Age, LDL, VLDL and Systolic blood pressure were close to the statistical significant level. Liver function tests were not significantly associated with parameters related to metabolic syndrome in this study.

Limitations

1. This is a cross sectional study hence incidence and cause effect relationship cannot be studied.
2. The study involves less sample size of about 100 study subjects. Hence studies with larger sample size will give more accurate conclusions.

REFERENCES

1. Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. *Diabetologist*. 2016 [cited 2018 Oct 11];59:1112–20.
2. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. *J Gastroenterol*. 2006 May;41(5):462–9.
3. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? {A} cross-sectional comparison with {Adult} {Treatment} {Panel} {III} criteria in nonobese nondiabetic subjects. *Diabetes Care*. 2008 Mar;31(3):562–8.
4. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. *Gastroenterology*. 2012 Apr;142(4):711–725, ed16.
5. Vanjiappan S, Hamide A, Ananthkrishnan R, Periyasamy SG, Mehalingam V. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. *Diabetes Metab Syndr Clin Res Rev [Internet]*. 2018 Jul [cited 2018/Oct/11];12(4):479–82. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1871402117304502>
6. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *JAMA*. 2015 Jun;313(22):2263–73.
7. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic {Fatty} {Liver} {Disease}

- {Review}: {Diagnosis}, {Treatment}, an {Outcomes}. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc*. 2015 Nov;13(12):2062–70.
8. Bedogni G, Bellentani S. Fatty liver: {How} frequent is it and why? : *Annals of Hepatology* 2004; 3(2):April-June: 63-65.
 9. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology [Internet]*. 2012 Jun [cited 2018/Oct/11];55(6):2005–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22488764>
 10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001 May 16 [cited 2018/Oct/13];285(19):2486–97. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11368702>.
 11. Coroian Aurelia SG, Aurelia C, Donca V, Emanuela F. Is the Non-Alcoholic Fatty Liver Disease Part of Metabolic Syndrome? *J Diabetes Metab*. 2015 Mar 21 [cited 2018 Oct 11];06(04):1–3. Available from: <https://www.omicsonline.org/open-access/is-the-nonalcoholic-fatty-liver-disease-part-of-metabolic-syndrome-2155-6156-1000526.php?aid=50813>
 13. ki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *lancet Diabetes Endocrinol*. 2014 Nov 1 [cited 2018 Oct 11];2(11):901–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24731669>
 15. 13.Coroian Aurelia SG, Aurelia C, Donca V, Emanuela F. Is the Non-Alcoholic Fatty Liver Disease Part of Metabolic Syndrome? *J Diabetic Mellitus*. 2015 Mar 21 [cited 2018 Oct 11];06(04):1–3. Available from: <https://www.omicsonline.org/open-access/is-the-nonalcoholic-fatty-liver-disease-part-of-metabolic-syndrome-2155-6156-1000526>.
 17. 14.Williams T. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease. *FPEssent*. 2015 Aug [cited 2018/Oct/11];435:24–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26280342>
 18. 15 .Banerjee S, Ghosh US, Dutta S. Clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. *J Assoc Physicians India* . 2008 Aug [cited 2018 Oct 10];56:593–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19051703>
 19. 16.Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. *Hepatology [Internet]*. 2005 Jul [cited 2018 Oct 10];42(1):44–52. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15895401>